A review of Traditional Chinese herbal medicine in management of COVID-19

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 59.65 million people worldwide and claimed the lives of over 1.4 million. The virus, first detected in late December 2019 in Wuhan, China, is the most significant public health problem since the 1918 Spanish flu pandemic. There are no effective and safe drugs that can be used to treat COVID-19 disease nor vaccine to prevent SARS-CoV-2 infection. Since the first cases were detected in Wuhan, several traditional Chinese herbal medicines have been used to treat this infection.

Now researchers led by David Lee from Bio-Organic and Natural Research Laboratory, McLean Hospital, Harvard Medical School, Belmont have summarized the experiences with the use of traditional Chinese herbal medicines for the management of COVID-19. Their study titled, “Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis,” was published in the January 2021 issue of the journal Phytomedicine.

Study: Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. Image Credit: Dragon Images / Shutterstock

Background

China has a rich history of traditional herbal medicines. Traditional Chinese herbal medicine (TCM) has been used for over 5,000 in over 300 epidemics that the nation has faced. When the COVID-19 pandemic emerged early this year, treatment with TCM was reported to have been used with over 90 percent efficacy.

Study particulars

This study was a systematic review of several traditional Chinese herbal medicines that were used in Wuhan,  looking at their efficacy in the management of COVID-19. At present, patients admitted to hospitals (except TCM hospitals) are primarily treated with western medicine as frontline treatment.

Principles of TCM use

The western medications used include antibiotics and painkillers. At present, over 100 herbal TCM formulae are available for use in epidemic related infections. Authors write, “TCM is now credited for the successful battle against COVID-19 in China”.

The ancient Chinese medical text Huangdi Neijing explains that 12 meridian lines run through the human body and help balance the immune system and provide good health. The lung meridian line interconnects with the large intestine functionally and controls the body fluid (water). The researchers write, “Expelling phlegm and relaxing the bowels with laxatives are common methods for treating lung diseases. Therefore, maintaining a smooth and open channel is an important function served by the lung meridian line.” Treatment of COVID-19 is basically to “expel the toxic moisture from the upper respiratory system and to improve intestinal obstruction.” They added that the TCM method of treatment tries to maintain the balance of the lung meridian system and to restore the lung and large intestine balance using acupuncture and herbal medicine.

Treatment of COVID-19 using TCM

TCM has been used as a first-line treatment for COVID-19 disease since the emergence of SARS-CoV-2. Qingfei Paidu decoction for example, has been used in a three-day course leading to an over 90 percent efficacy.

The team of researchers wrote, “The Chinese government announced that TCM is one of the recommended therapeutic options for the treatment of COVID-19 in the third version COVID-19 treatment guidelines, published on January

Read more

Biodesix Announces Data from Three Studies on Lung Nodule Diagnosis and Management to be Shared at CHEST Annual Meeting 2020

Research Evaluates Risk Classification for Patients with Lung Nodules

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, recently published data from three clinical studies, which found important new information on diagnosis and management of lung nodules. Data from these studies, which are being presented at the American College of Chest Physicians (CHEST) annual meeting, demonstrate the value of the Nodify Lung™ testing strategy and confirm previously reported performance of the Nodify XL2® and Nodify CDT™ tests.

Abstract #A1464/Poster #P1319: Identification of Likely Malignant Indeterminate Pulmonary Nodules by Analysis of Autoantibodies Against Lung Cancer-Associated Antigens
Authors: Kevin Doubleday, James Jett, Laura Peek, Trevor Pitcher
A retrospective analysis of the PANOPTIC study found that the blood-based Nodify CDT test accurately identified patients whose lung nodules were likely malignant, which confirms previously reported test performance. Patients identified as Nodify CDT positive may benefit from a more rapid evaluation and intervention for cancer.

Abstract #A1468/Poster #P1325: Lung Nodule Integrated Classifier Biomarker: First Data with Real-World Clinical Use
Authors: James Jett, Kerstin Pohl, Gerard Silvestri, Steven Springmeyer
A real-world clinical use study demonstrates the utility of the blood-based Nodify XL2 test for identifying patients with likely benign lung nodules by integrating the patients’ blood-based protein data with clinical risk factors, resulting in a large proportion of low to moderate risk nodules being reclassified as very low risk. Risk reclassification can reduce invasive procedures on benign nodules and ultimately lead to improved nodule management.

Abstract #A1476/Poster #P1324: Use of Two Blood-Based Biomarker Tests in Series to Reclassify Risk of Indeterminate Pulmonary Nodules
Authors: Kevin Doubleday, James Jett, Laura Peek, Trevor Pitcher, Steven Springmeyer
Data suggest that while standard risk assessment for lung cancer is imprecise, it can be improved with the blood-based Nodify Lung testing strategy. By combining the Nodify CDT and Nodify XL2 tests, patients can be more appropriately assessed for risk of malignancy to help reduce unnecessary procedures on patients with benign nodules and delays in treatment for patients with cancer.

About Biodesix
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy, consisting of the Nodify XL2™ and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges

Read more